Table 1

Demographic and clinical characteristics of episodes of allopurinol users (baseline with no atrial fibrillation; baseline was longest possible and at least 365 days)

 All episodesAtrial fibrillation during the follow-up
YesNop Value
Total, N (episodes)924413667878N/A
Age77.2 (7.0)77.0 (7.0)78.2 (7.2)<0.0001
Gender, N (%)0.81
 Male4020 (43.5)590 (43.2)3430 (43.5)
 Female5224 (56.5)776 (56.8)4448 (56.5)
Race/ethnicity, N (%)<0.0001
 White6595 (71.3)1049 (76.8)5546 (70.4)
 Black1434 (15.5)180 (13.2)1254 (15.9)
 Hispanic301 (3.3)39 (2.9)262 (3.3)
 Asian681 (7.4)71 (5.2)610 (7.7)
 Native American38 (0.4)5 (0.4)33 (0.4)
 Other/unknown48 (2.1)22 (1.6)173 (2.2)
Region, N (%)0.016
 North-East1411 (15.3)236 (17.3)1175 (14.9)
 Mid-West2285 (24.7)350 (25.6)1935 (24.6)
 South3693 (40.0)542 (39.7)3151 (40.0)
 West1855 (20.1)238 (17.4)1617 (20.5)
Charlson–Romano comorbidity score4.89 (3.77)5.44 (3.70)4.80 (3.77)<0.0001